I am a board-certified hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center.
My clinical expertise is in treating patients with chronic myeloid leukemia (CML) as well as other myeloproliferative disorders, including myelofibrosis, polycythemia and thrombocytosis as well as less common conditions such as eosinophillic and mast cell disorders. My patient care philosophy is to offer in-depth explanation regarding diagnoses and to engage in active partnership with my patients and their referring providers to personalize decision-making and monitoring given the chronic nature of the disorders I treat.
Before joining Memorial Sloan Kettering, I was on the faculty of Oregon Health and Sciences University for 13 years. There I directed the CML clinical trial program and was involved in the early development and sentinel clinical study of targeted therapy for CML from imatinib (Gleevec) onwards. I completed both residency and fellowship training at the NewYork-Presbyterian Hospital / Weill Cornell Medical College in Manhattan.
The treatment of myeloproliferative neoplasms (MPNs), especially CML, has seen unprecedented advance in the last 15 years. Development and approval of a number of targeted ‘kinase inhibitor’ therapies has led to the realization of long-term treatment success and a potential functional cure for CML and discovery of therapeutic targets in other MPNs. Careful decision-making is very important from diagnosis onward in MPNs given the array of options and potential for novel approaches. Areas of clinical focus for me include early optimization of therapy, understanding the basis and management of emerging side effects and managing resistance and intolerance to therapy.
Memorial Sloan Kettering has significant expertise in the molecular characterization of MPNs and a distinguished history in the development of cutting-edge effective therapies for a wide variety of leukemias. The MPN program within the Leukemia Service at Memorial Sloan Kettering Cancer Center is in an excellent position to continue research into the optimization of CML therapy and to develop new and better treatments for MPNs broadly. We have a group of clinicians focused on MPNs and an expanding clinical trials program to answer key questions and the program is dedicated to bring our patients novel therapies, best monitoring practices and long-term treatment success.
- Clinical Expertise: Chronic Myeloid Leukemia; Myelofibrosis; Polycythemia; Thrombocytosis, Other Myeloproliferative Disorders
- Languages Spoken: English
- Education: MD, Dartmouth Medical School
- Residencies: NewYork-Presbyterian Hospital/Weill Cornell Medical Center
- Fellowships: NewYork-Presbyterian Hospital/Weill Cornell Medical Center
- Board Certifications: Internal Medicine; Hematology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Michael J. Mauro
- A Phase I Study of ABL001 in Patients with Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- A Phase II Study Evaluating a Range of Doses of Ponatinib for Resistant Chronic Myelogenous Leukemia
- LAST: The Life After Stopping Tyrosine Kinase Inhibitors Study
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more